Full Press Release Details
Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY Endovascular
agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional
procedures between two facilities within the Corewell Health
Mass., August 22, 2024 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular
Robotic System, announces that it entered into a Phase 2 collaboration agreement with Corewell HealthTM that will continue
their collaboration to advance remote telesurgery for endovascular procedures. The Company had previously announced positive results
from the first phase, which demonstrated LIBERTY's technical capabilities and outlined potential future applications in a range
of endovascular interventions, including the feasibility of LIBERTY to support the remote telesurgery project.
Phase 2, the Company and Corewell Health will work together to develop the capabilities to perform simulated cardiovascular interventional
procedures with LIBERTY across two sites within the Corewell Health system which are 5 miles apart.
project is led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health
in West Michigan. Following the completion of Phase 1, Dr. Madder and colleagues published a manuscript in the Journal of the American
College of Cardiology: Cardiovascular Interventions, highlighting the Technical Success of Coronary Guidewire and Stent Delivery Using
a Novel Miniaturized Robotic System in a Pre-Clinical Study.
telesurgery capabilities is an important part of our long-term strategy for LIBERTY," said Harel Gadot, CEO, President and Chairman
of Microbot Medical. "We believe that physicians in the U.S. and around the globe want to increase access to care for patients
in remote locations, and we are excited to continue our collaboration with Corewell Health and Dr. Madder on this next phase of development."
Madder's manuscript is available at: https://doi.org/10.1016/j.jscai.2024.102148
Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
Investigational LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used
in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation
exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System's remote operation
has the potential to be the first system to democratize endovascular interventional procedures.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY
Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether
the Company's pivotal study in humans is successful, any failure or inability to recruit physicians and clinicians to serve as
primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new
and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from
the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports
filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.